Trials / Recruiting
RecruitingNCT06068543
Reducing Frailty for Older Cancer Survivors Using Supplements II
A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (estimated)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epigallocatechin-3-Gallate (EGCG) | 800mg Epigallocatechin-3-Gallate (EGCG) |
| DRUG | Microcrystalline cellulose (MCC) | 800mg microcrystalline cellulose (MCC) |
| DIETARY_SUPPLEMENT | Ascorbic Acid (Vitamin C) | 250mg Ascorbic Acid (Vitamin C) taken one time daily for 12 weeks |
Timeline
- Start date
- 2024-10-25
- Primary completion
- 2030-01-01
- Completion
- 2030-12-31
- First posted
- 2023-10-05
- Last updated
- 2026-03-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06068543. Inclusion in this directory is not an endorsement.